{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:43:01Z","timestamp":1793364181841,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This investigator initiated phase 2 clinical trial was sponsored by Salspera."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04307-0","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:20:08Z","timestamp":1769491208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Gerald","family":"Batist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Schottel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Moradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Saltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4307_CR1","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"issue":"27","key":"4307_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. Lancet 395(27):2008\u20132020. https:\/\/doi.org\/10.1016\/S0140-6736(20)30974-0","journal-title":"Lancet"},{"issue":"1","key":"4307_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16199","volume":"5","author":"A Klein-Brill","year":"2022","unstructured":"Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D (2022) Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Netw Open 5(1):e2216199. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16199","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4307_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P et al (2024) NALIRIFOX, FOLFIRINOX, and Gemcitabine with Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: a systematic review and meta-analysis. JAMA Netw Open 7(1):e2350756. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50756","journal-title":"JAMA Netw Open"},{"key":"4307_CR5","unstructured":"https:\/\/clinicaltrials.gov\/search?cond=Metastatic%20Pancreatic%20Cancer&aggFilters=status:rec&page=2"},{"issue":"7","key":"4307_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2174\/1874467215666220128161647","volume":"15","author":"T Rajpurohit","year":"2022","unstructured":"Rajpurohit T, Bhattacharya S (2022) Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma. Curr Mol Pharmacol 15(7):904\u2013928. https:\/\/doi.org\/10.2174\/1874467215666220128161647","journal-title":"Curr Mol Pharmacol"},{"issue":"4","key":"4307_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/0929866530666230213113835","volume":"30","author":"L Periyasamy","year":"2023","unstructured":"Periyasamy L, Murugantham B, Sundaraj R, Krishnamoorthi S, Muthusami S (2023) Screening of MMP-2 inhibiting phytoconstituents for the development of newer pancreatic cancer treatment modalities. Protein Pept Lett 30(4):304\u2013313. https:\/\/doi.org\/10.2174\/0929866530666230213113835","journal-title":"Protein Pept Lett"},{"key":"4307_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111429","volume":"137","author":"C Xue","year":"2021","unstructured":"Xue C, Li G, Lu J, Luo J, Jia J (2021) Novel insights for lncRNA MAGI2-AS3 in solid tumors. Biomed Pharmacother 137:111429. https:\/\/doi.org\/10.1016\/j.biopha.2021.111429","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"4307_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-37000-8","volume":"13","author":"Q Shi","year":"2023","unstructured":"Shi Q, Xue C, Zeng Y, Gu X, Wang J, Li L (2023) A novel prognostic model for hepatocellular carcinoma based on pyruvate metabolism-related genes. Sci Rep 13(16):9780. https:\/\/doi.org\/10.1038\/s41598-023-37000-8","journal-title":"Sci Rep"},{"key":"4307_CR10","doi-asserted-by":"publisher","unstructured":"Forbes, Coffin, Deng, Evgin, Fiering, Giacalone, Gravekamp, Gulley, Gunn, Hoffman, Kaur,Liu, Lyerly, Marciscano, Moradian, Ruppel, Saltzman, Tattersall, Thorne, Vile, Zhang,Zhou, & McFadden. (2018). White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer, 6(1), 78. https:\/\/doi.org\/10.1186\/s40425-018-0381-3","DOI":"10.1186\/s40425-018-0381-3"},{"key":"4307_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41587-025-02623-x","volume":"43","author":"ER Ballister","year":"2025","unstructured":"Ballister ER, Michels A, Vincent RL et al (2025) The emerging landscape of engineered bacteria cancer therapies. Nat Biotechnol 43:672\u2013676. https:\/\/doi.org\/10.1038\/s41587-025-02623-x","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4307_CR12","first-page":"145","volume":"11","author":"CP Heise","year":"1996","unstructured":"Heise CP, Saltzman DA, Hasz DE, Zebede M, Kelly SM, Curtiss IIIR, Leonard AS, Anderson PM (1996) Attenuated Salmonella typhimurium containing interleukin-2 decreases number of MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother Radiopharm 11(2):145\u2013153","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"4307_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0022-3468(97)90198-6","volume":"32","author":"DA Saltzman","year":"1997","unstructured":"Saltzman DA, Katsanis E, Hasz DE, Vigdorovich V, Curtiss IIIRE, Kelly SM, Anderson PM, Leonard AS (1997) Anti-tumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2. J Pediatr Surg 32(2):301\u2013306","journal-title":"J Pediatr Surg"},{"key":"4307_CR14","first-page":"37","volume":"12910","author":"DA Saltzman","year":"1997","unstructured":"Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R, Anderson PM, Leonard AS (1997) Hepatic and Splenic Colonization for the Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2: A Novel Anti-Tumor Agent. Cancer Biother Radiopharm 12910:37\u201345","journal-title":"Cancer Biother Radiopharm"},{"key":"4307_CR15","doi-asserted-by":"crossref","unstructured":"Soto LJ, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA; Generation of Immunity to Hepatic Metastases by Attenuated Salmonella typhimurium, Ann Surg Onc, 11(2)suppl: S107, 2004.","DOI":"10.1007\/BF02524146"},{"issue":"S1","key":"4307_CR16","first-page":"30","volume":"23","author":"LJ Soto","year":"2002","unstructured":"Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA (2002) Attenuated Salmonella typhimurium prevents the establishment of hepatic colorectal metastases and improves survival in a murine model. Tumor Biol 23(S1):30","journal-title":"Tumor Biol"},{"issue":"6","key":"4307_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jpedsurg.2004.02.042","volume":"39","author":"LJ Soto","year":"2004","unstructured":"Soto LJ, Sorenson BS, Nelson B, Solis S, Leonard AS, Saltzman DA (2004) Preferential proliferation of attenuated Salmonella typhimurium within neuroblastoma. J Pediatr Surg 39(6):937\u2013940","journal-title":"J Pediatr Surg"},{"issue":"6","key":"4307_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jpedsurg.2005.03.015","volume":"40","author":"SJ Barnett","year":"2005","unstructured":"Barnett SJ, Soto IIILJ, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA (2005) Salmonella typhimurium invades and decreases tumor burden in neuroblastoma. J Pediatr Surg 40(6):993\u2013998","journal-title":"J Pediatr Surg"},{"key":"4307_CR19","doi-asserted-by":"crossref","unstructured":"Brent S. Sorenson, BS, Kaysie L. Banton, MD, Natalie L Frykman, BS, Robert D. Acton MD, Arnold S. Leonard MD, PhD, Daniel A. Saltzman, MD, PhD. Attenuated Salmonella typhimurium with IL-2 gene Reduces Pulmonary Metastases in a Model of Osteosarcoma; Clinical Orthopaedics and Related Research. 466(6): 1285\u201391. 2008.","DOI":"10.1007\/s11999-008-0243-2"},{"issue":"3","key":"4307_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/vms3.32","volume":"2","author":"SE Fritz","year":"2016","unstructured":"Fritz SE, Henson MS, Greengard E, Winter AL, Stuebner KM, Yoon U, Wilke VL, Borgatti A, Augustin LB, Modiano JF, Saltzman DA (2016) A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. Veterinary Medicine and Science 2(3):179\u2013190 (PMID: 29067193)","journal-title":"Veterinary Medicine and Science"},{"issue":"7","key":"4307_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CJI.0000000000000325","volume":"43","author":"T Gniadek","year":"2020","unstructured":"Gniadek T, Augustin L, Schottel J, Leonard A, Saltzman D, Greeno E, Batist G (2020) A phase I, dose escalation, single dose trial of oral attenuated Salmonella typhimurium containing human IL-2 in patients with metastatic gastrointestinal cancers. J Immunother 43(7):217\u2013221. https:\/\/doi.org\/10.1097\/CJI.0000000000000325","journal-title":"J Immunother"},{"issue":"2","key":"4307_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4307_CR23","unstructured":"https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/aeguidelines.pdf"},{"key":"4307_CR24","unstructured":"https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/"},{"key":"4307_CR25","doi-asserted-by":"publisher","unstructured":"Curtiss, & Kelly. (1987). Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun, 55(12),3035\u20133043. https:\/\/doi.org\/10.1128\/iai.55.12.3035-3043.1987","DOI":"10.1128\/iai.55.12.3035-3043.1987"},{"key":"4307_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y et al (2023) Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer 22:121. https:\/\/doi.org\/10.1186\/s12943-023-01826-7","journal-title":"Mol Cancer"},{"key":"4307_CR27","unstructured":"Batist G, Park JY, Drees J, Kangas T, Saltzman D. Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report. Clinical Oncology: Case Reports. 2020;3(3)."},{"issue":"5","key":"4307_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijantimicag.2012.01.019","volume":"39","author":"LP Jordheim","year":"2012","unstructured":"Jordheim LP, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, Dumontet C, Freney J, Dol\u00e9ans-Jordheim A (2012) Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. Int J Antimicrob Agents 39(5):444\u2013447. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.01.019","journal-title":"Int J Antimicrob Agents"},{"issue":"19","key":"4307_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"12","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardi\u00e8re C, Bennouna J, Bachet JB, Khemissa-Akouz F, P\u00e9r\u00e9-Verg\u00e9 D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 12(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"13","key":"4307_CR30","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.12998\/wjcc.v9.i13.2969","volume":"9","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Jung YJ, Moon SH (2021) Immunotherapy for pancreatic cancer. World J Clin Cases 9(13):2969\u20132982. https:\/\/doi.org\/10.12998\/wjcc.v9.i13.2969","journal-title":"World J Clin Cases"},{"key":"4307_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, Xu D, Liao Mm et al (2024) Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol 8:199. https:\/\/doi.org\/10.1038\/s41698-024-00681-z","journal-title":"NPJ Precis Oncol"},{"key":"4307_CR32","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1038\/s41467-019-10015-4","volume":"10","author":"N Kedia-Mehta","year":"2019","unstructured":"Kedia-Mehta N, Finlay DK (2019) Competition for nutrients and its role in controlling immune responses. Nat Commun 10:2123. https:\/\/doi.org\/10.1038\/s41467-019-10015-4","journal-title":"Nat Commun"},{"key":"4307_CR33","doi-asserted-by":"crossref","unstructured":"Saltzman DA, Augustin LB, Leonard AS, Mertensotto M, and Schottel J: Low Dose Chemotherapy Combined with Attenuated Salmonella Significantly Reduces Tumor Burden and is Less Toxic than High Dose Chemotherapy in an Autochthonous Murine Model of Breast Cancer. Surgery, 163(3):509\u2013514, 2018. PMID 29229318","DOI":"10.1016\/j.surg.2017.09.036"},{"issue":"14","key":"4307_CR34","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-17-2953","volume":"24","author":"B Ribba","year":"2018","unstructured":"Ribba B, Boetsch C, Nayak T, Grimm HP, Charo J, Evers S, Klein C, Tessier J, Charoin JE, Phipps A, Pisa P, Teichgr\u00e4ber V (2018) Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy. Clin Cancer Res 24(14):3325\u20133333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2953","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4307_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040632","volume":"8","author":"F Le Louedec","year":"2020","unstructured":"Le Louedec F, Leenhardt F, Marin C, Chatelut \u00c9, Evrard A, Ciccolini J (2020) Cancer immunotherapy dosing: a pharmacokinetic\/pharmacodynamic perspective. Vaccines 8(4):632. https:\/\/doi.org\/10.3390\/vaccines8040632","journal-title":"Vaccines"},{"key":"4307_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H et al (2024) Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol 17:40. https:\/\/doi.org\/10.1186\/s13045-024-01561-6","journal-title":"J Hematol Oncol"},{"key":"4307_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144\u2013150. https:\/\/doi.org\/10.1038\/s41586-023-06063-y","journal-title":"Nature"},{"issue":"1","key":"4307_CR38","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.606","volume":"7","author":"JS Wasser","year":"2023","unstructured":"Wasser JS, Greenblatt DJ (2023) Applying real-world data from expanded-access (\u201ccompassionate use\u201d) patients to drug development. J Clin Transl Sci 7(1):e181. https:\/\/doi.org\/10.1017\/cts.2023.606","journal-title":"J Clin Transl Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04307-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:20:10Z","timestamp":1769491210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4307"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04307-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Daniel Saltzman is a Professor of Surgery and Pediatrics and the Chief of Pediatric Surgery at the University of Minnesota. Dr. Saltzman is also the co-founder and chief medical officer of Salspera. Salspera is a biotechnology company centered around bacterial based immunotherapeutics and hold the patents for Salmonella-IL2. This conflict has been extensively disclosed and is managed by the Office of Conflict Administration at the University of Minnesota.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"60"}}